The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected populations. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, parasitic worms’ diseases, mycetoma, dengue, paediatric HIV, cryptococcal meningitis, and hepatitis C. Its research priorities include children’s health; gender equity and gender-responsive R&D; and diseases impacted by climate change. Since its creation in 2003, DNDi has collaborated with public and private partners worldwide to deliver 13 new treatments for six deadly diseases, saving millions of lives.
DNDi will oversee the data management of the clinical trial (WP3) through its Nairobi-based Data Management and Biostatistics Centre, the only non-profit centre of its kind in Africa. DNDi will also support INRB with the implementation of the clinical trial (WP3), continuing a partnership established in 2005 for research in the DRC, which has included sleeping sickness and filarial diseases. DNDi will be supporting the development of the clinical trial protocol and the preparation of the submission package to the Ethics committees / Regulatory Authorities. Offering regulatory support and building on its extensive experience in engaging with regulatory authorities, DNDi will advocate for access and affordability, capacity building, and promotion of ethical practices in Africa.
“WINGS-4-FGS is a fantastic opportunity for partners across continents to become one powerful voice for women and girls living with FGS.”
“It is an honour to work alongside the WINGS-4-FGS partners on this project to improve the lives of women and young girls.”
